Reverse Phase Protein Array (RPPA) technology is a powerful new tool for quantitative and multiplexed analysis of cellular protein networks in a high-throughput manner. It is several orders of magnitude more sensitive than other protein-based techniques. The source of material is therefore extremely diverse ranging from standard cell culture cell lines and complex 3D cultures to freshly extracted patient samples and formalin-fixed, paraffin-embedded (FFPE) fixed tissues. Such unprecedented flexibility and sensitivity makes the RPPA platform an ideal complement to the current genomics approaches for identifying novel rational drug combinations and biomarkers as well as for studying drugs’ mechanism of action. Beside its clear applications in cancer tissue profiling, this method has a general utility for monitoring protein dynamics in any experimental system.
The ACRF Translational RPPA platform is now fully accessible to researchers Australia-wide as part of the suite of services provided by the Victorian Centre for Functional Genomics (VCFG), housed at the Peter MacCallum Cancer Centre (and the Victorian Comprehensive Cancer Centre from June 2016). The platform offers experimental design guidance, direct lysate submission, selection of a vast range of verified antibodies for your screen and bioinformatic analysis. This poster will outline the experimental workflow and the power of high-throughput proteomics.